Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medicenna Therapeutics Corp (MDNA.TO)

Medicenna Therapeutics Corp (MDNA.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 184,203
  • Shares Outstanding, K 76,433
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,466 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 3.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.05
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings $-0.05 on 07/31/24
  • Next Earnings Date 11/12/24 [--]
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.06
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +17.79%
on 10/08/24
2.62 -6.49%
on 11/01/24
+0.36 (+17.22%)
since 10/07/24
3-Month
1.82 +34.62%
on 10/01/24
2.63 -6.84%
on 09/04/24
+0.34 (+16.11%)
since 08/07/24
52-Week
0.38 +544.74%
on 12/20/23
2.98 -17.79%
on 06/03/24
+1.99 (+432.61%)
since 11/07/23

Most Recent Stories

More News
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

OTCM : 51.7500 (-4.12%)
MDNA.TO : 2.47 (+2.49%)
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp.

Announced today that, as planned and previously announced, new data from two of its preclinical programs ...

MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp.

Will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, ...

MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp.

Announced today that the American Society of Clinical Oncology decided to reverse its decision and to ...

MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp.

Presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions ...

MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp

Announced that CEO Dr. Fahar Merchant, President and CEO will present and participate in one-on-one ...

MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp

Announced today that two posters will be presented at the American Association for Cancer Research Annual ...

MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp.

Today announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...

MDNA.TO : 2.47 (+2.49%)
Stocks in play: Medicenna Therapeutics Corp.

Today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only ...

MDNA.TO : 2.47 (+2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent...

See More

Key Turning Points

3rd Resistance Point 2.60
2nd Resistance Point 2.52
1st Resistance Point 2.46
Last Price 2.47
1st Support Level 2.32
2nd Support Level 2.24
3rd Support Level 2.18

See More

52-Week High 2.98
Last Price 2.47
Fibonacci 61.8% 1.99
Fibonacci 50% 1.68
Fibonacci 38.2% 1.37
52-Week Low 0.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar